Engineering better specimen quality for RNA disruption assay and other RNA genomic diagnostic applications (2012)


Human Health


Rna Diagnostics Inc, an early stage molecular diagnostics company, is developing assays aimed at assisting in the management of cancer chemotherapy.  The company will use the PBDF investment to further develop and validate their lead product, the RNA Disruption Assay™ (RDA™). This assay is designed to monitor a patient’s response to chemotherapy earlier in treatment than current methods, and has the potential to be a valuable tool in terms of helping provide a personalized approach to chemotherapy management.